Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Hirotsugu UemuraHiroji UemuraSatsohi NagamoriYoshiaki WakumotoGo KimuraHiroaki KikukawaAkira YokomizoAtsushi MizokamiTakeo KosakaNaoya MasumoriYoshihide KawasakiJunji YoneseYasutomo NasuSatoshi FukasawaTakayuki SugiyamaSeigo KinuyaMakoto HosonoIku YamaguchiTakashi AkagawaNobuaki MatsubaraPublished in: International journal of clinical oncology (2019)
In Japanese patients with symptomatic mCRPC and bone metastases, radium-223 had a favorable long-term safety profile with no second primary malignancies reported. Taken together with median OS, which was comparable to that in the pivotal phase III ALSYMPCA study, these results support continued benefit from radium-223 in Japanese patients with mCRPC.